Inhibition of platelet activation and thrombus formation by adenosine and inosine: Studies on their relative contribution and molecular modeling

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Fuentes, Eduardo ^a,b   Pereira, Jaime ^c   Mezzano, Diego ^c   Alarcón, Marcelo ^a,b   Caballero, Julio ^a   Palomo, Iván ^a,b  

^a UNIVERSIDAD DE TALCA   (Chile)

^b Centro de Estudios en Alimentos Procesados (CEAP)   (Chile)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 9 (TETRAHYDRO 2 FURYL)ADENINE; ACETYLSALICYLIC ACID; ADENOSINE; ADENOSINE A2 RECEPTOR; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; AMIDE; ASPARAGINE; CD40 LIGAND; COLLAGEN; CYCLIC AMP; GLUTAMINE; INOSINE; PADGEM PROTEIN; PHOSPHATIDYLSERINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; MOLECULAR DOCKING; MOLECULAR MODEL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION; ANIMAL; BIOLOGICAL MODEL; BLOOD CLOTTING; DRUG EFFECTS; METABOLISM; THROMBOCYTE; THROMBOSIS;

ADENOSINE; ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; COLLAGEN; HUMANS; INOSINE; MALE; MICE; MODELS, BIOLOGICAL; PLATELET ADHESIVENESS; THROMBOSIS;

EID: 84911479262     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112741     Document Type: Article

References (62)

1. Palomo GI, Icaza NG, Mujica EV, Nunez FL, Leiva ME, et al. (2007) Prevalence of cardiovascular risk factors in adult from Talca, Chile. Rev Med Chil 135: 904-912.
2. Bautista LE, Orostegui M, Vera LM, Prada GE, Orozco LC, et al. (2006) Prevalence and impact of cardiovascular risk factors in Bucaramanga, Colombia: results from the Countrywide Integrated Noncommunicable Disease Intervention Programme (CINDI/CARMEN) baseline survey. Eur J Cardiovasc Prev Rehabil 13: 769-775.
3. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V (1999) Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 100: 1481-1492.
4. Mujica V, Urzua A, Leiva E, Diaz N, Moore-Carrasco R, et al. (2010) Intervention with education and exercise reverses the metabolic syndrome in adults. J Am Soc Hypertens 4: 148-153.
5. Willoughby S, Holmes A, Loscalzo J (2002) Platelets and cardiovascular disease. Eur J Cardiovasc Nurs 1: 273-288.
6. Sagel J, Colwell JA, Crook L, Laimins M (1975) Increased platelet aggregation in early diabetus mellitus. Ann Intern Med 82: 733-738.
7. Palomo I, Moore-Carrasco R, Alarcon M, Rojas A, Espana F, et al. (2010) Pathophysiology of the proatherothrombotic state in the metabolic syndrome. Front Biosci (Schol Ed) 2: 194-208.
8. Ruggeri ZM (1997) Mechanisms initiating platelet thrombus formation. Thromb Haemost 78: 611-616.
9. Chakhtoura EY, Shamoon FE, Haft JI, Obiedzinski GR, Cohen AJ, et al. (2000) Comparison of platelet activation in unstable and stable angina pectoris and correlation with coronary angiographic findings. Am J Cardiol 86: 835-839.
10. Galliera E, Corsi MM, Banfi G (2012) Platelet rich plasma therapy: inflammatory molecules involved in tissue healing. J Biol Regul Homeost Agents 26: 35S-42S.
11. Fuentes QE, Fuentes QF, Andres V, Pello OM, de Mora JF, et al. (2013) Role of platelets as mediators that link inflammation and thrombosis in atherosclerosis. Platelets 24: 255-262.
12. Collins B, Hollidge C (2003) Antithrombotic drug market. Nat Rev Drug Discov 2: 11-12.
13. Palomo I, Toro C, Alarcon M (2008) The role of platelets in the pathophysiology of atherosclerosis (Review). Mol Med Rep 1: 179-184.
14. Ji X and Hou M (2011) Novel agents for anti-platelet therapy. J Hematol Oncol 4: 44.
15. Patrono C, Baigent C, Hirsh J, Roth G (2008) Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 199S-233S.
16. Tantry US, Etherington A, Bliden KP, Gurbel PA (2006) Antiplatelet therapy: current strategies and future trends. Future Cardiol 2: 343-366.
17. Lerea KM, Glomset JA, Krebs EG (1987) Agents that elevate cAMP levels in platelets decrease thrombin binding. J Biol Chem 262: 282-288.
18. Lerea KM, Glomset JA (1987) Agents that elevate the concentration of cAMP in platelets inhibit the formation of a NaDodSO4-resistant complex between thrombin and a 40-kDa protein. Proc Natl Acad Sci U S A 84: 5620-5624.
19. Fredholm BB, AP IJ, Jacobson KA, Klotz KN, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53: 527-552.
20. Hasko G, Linden J, Cronstein B, Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7: 759-770.
21. Cristalli G, Costanzi S, Lambertucci C, Lupidi G, Vittori S, et al. (2001) Adenosine deaminase: functional implications and different classes of inhibitors. Med Res Rev 21: 105-128.
22. Hasko G, Kuhel DG, Nemeth ZH, Mabley JG, Stachlewitz RF, et al. (2000) Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. J Immunol 164: 1013-1019.
23. Ritchie JL, Alexander HD, Rea IM (2000) Flow cytometry analysis of platelet P-selectin expression in whole blood-methodological considerations. Clin Lab Haematol 22: 359-363.
24. Born GV, Cross MJ (1963) The Aggregation of Blood Platelets. J Physiol 168: 178-195.
25. Conant CG, Schwartz MA, Nevill T, Ionescu-Zanetti C (2009) Platelet adhesion and aggregation under flow using microfluidic flow cells. J Vis Exp.
26. Friesner R, Banks J, Murphy R, Halgren T, Klicic J, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry 47: 1739-1749.
27. Munoz C, Adasme F, Alzate-Morales JH, Vergara-Jaque A, Kniess T, et al. (2012) Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations. J Mol Graph Model 32: 39-48.
28. Jorgensen W, Maxwell D, Tirado-Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. Journal of the American Chemical Society 118: 11225-11236.
29. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP (1997) Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 11: 425-445.
30. Przyklenk K, Whittaker P (2007) Adaptation of a photochemical method to initiate recurrent platelet-mediated thrombosis in small animals. Lasers Med Sci 22: 42-45.
31. Abramoff MD, Magalhaes PJ, Ram SJ (2004) Image Processing with ImageJ. Biophotonics International 11: 36-42.
32. Antczak AJ, Singh N, Gay SR, Worth RG (2010) IgG-complex stimulated platelets: a source of sCD40L and RANTES in initiation of inflammatory cascade. Cell Immunol 263: 129-133.
33. Kim J, Jiang Q, Glashofer M, Yehle S, Wess J, et al. (1996) Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. Mol Pharmacol 49: 683-691.
34. Fuentes E, Castro R, Astudillo L, Carrasco G, Alarcón M, et al. (2012) Bioassay-Guided Isolation and HPLC Determination of Bioactive Compound That Relate to the Antiplatelet Activity (Adhesion, Secretion, and Aggregation) from Solanum lycopersicum. Evidence-Based Complementary and Alternative Medicine: 1-10.
35. Wang J, Huang ZG, Cao H, Wang YT, Hui P, et al. (2008) Screening of antiplatelet aggregation agents from Panax notoginseng using human platelet extraction and HPLC-DAD-ESI-MS/MS. J Sep Sci 31: 1173-1180.
36. Fuentes E, Castro R, Astudillo L, Carrasco G, Alarcon M, et al. (2012) Bioassay-Guided Isolation and HPLC Determination of Bioactive Compound That Relate to the Antiplatelet Activity (Adhesion, Secretion, and Aggregation) from Solanum lycopersicum. Evid Based Complement Alternat Med 2012: 147031.
37. Anfossi G, Russo I, Massucco P, Mattiello L, Cavalot F, et al. (2002) Adenosine increases human platelet levels of cGMP through nitric oxide: possible role in its antiaggregating effect. Thromb Res 105: 71-78.
38. Minamino T, Kitakaze M, Asanuma H, Tomiyama Y, Shiraga M, et al. (1998) Endogenous adenosine inhibits P-selectin-dependent formation of coronary thromboemboli during hypoperfusion in dogs. J Clin Invest 101: 1643-1653.
39. Altman R, Rouvier J, Weisenberger H (1985) Identification of platelet inhibitor present in the melon (Cucurbitacea cucumis melo). Thromb Haemost 53: 312-313.
40. Dutta-Roy AK, Crosbie L, Gordon MJ (2001) Effects of tomato extract on human platelet aggregation in vitro. Platelets 12: 218-227.
41. Hasko G, Sitkovsky MV, Szabo C (2004) Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol Sci 25: 152-157.
42. Hsiao G, Lin KH, Chang Y, Chen TL, Tzu NH, et al. (2005) Protective mechanisms of inosine in platelet activation and cerebral ischemic damage. Arterioscler Thromb Vasc Biol 25: 1998-2004.
43. Burger PC, Wagner DD (2003) Platelet P-selectin facilitates atherosclerotic lesion development. Blood 101: 2661-2666.
44. Storey RF, Judge HM, Wilcox RG, Heptinstall S (2002) Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost 88: 488-494.
45. Libersan D, Rousseau G, Merhi Y (2003) Differential regulation of P-selectin expression by protein kinase A and protein kinase G in thrombin-stimulated human platelets. Thromb Haemost 89: 310-317.
46. Fuentes E, Badimon L, Caballero J, Padro T, Vilahur G, et al. (2013) Protective mechanisms of adenosine 5′-monophosphate in platelet activation and thrombus formation. Thromb Haemost 111.
47. Inoue O, Suzuki-Inoue K, Dean WL, Frampton J, Watson SP (2003) Integrin alpha2beta1 mediates outside-in regulation of platelet spreading on collagen through activation of Src kinases and PLCgamma2. J Cell Biol 160: 769-780.
48. Aukrust P, Muller F, Ueland T, Berget T, Aaser E, et al. (1999) Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100: 614-620.
49. Wagner DD, Burger PC (2003) Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 23: 2131-2137.
50. Harding SA, Sommerfield AJ, Sarma J, Twomey PJ, Newby DE, et al. (2004) Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis 176: 321-325.
51. Setianto BY, Hartopo AB, Gharini PP, Anggrahini DW, Irawan B (2010) Circulating soluble CD40 ligand mediates the interaction between neutrophils and platelets in acute coronary syndrome. Heart Vessels 25: 282-287.
52. Daniel JL, Dangelmaier C, Jin J, Kim YB, Kunapuli SP (1999) Role of intracellular signaling events in ADP-induced platelet aggregation. Thromb Haemost 82: 1322-1326.
53. Yang D, Chen H, Koupenova M, Carroll SH, Eliades A, et al. (2010) A new role for the A2b adenosine receptor in regulating platelet function. J Thromb Haemost 8: 817-827.
54. Loyau S, Dumont B, Ollivier V, Boulaftali Y, Feldman L, et al. (2012) Platelet glycoprotein VI dimerization, an active process inducing receptor competence, is an indicator of platelet reactivity. Arterioscler Thromb Vasc Biol 32: 778-785.
55. Enomoto Y, Adachi S, Doi T, Natsume H, Kato K, et al. (2011) cAMP regulates ADP-induced HSP27 phosphorylation in human platelets. Int J Mol Med 27: 695-700.
56. Hoffmeister HM, Betz R, Fiechtner H, Seipel L (1987) Myocardial and circulatory effects of inosine. Cardiovasc Res 21: 65-71.
57. Fredholm BB, Irenius E, Kull B, Schulte G (2001) Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 61: 443-448.
58. Zhao Z, Makaritsis K, Francis CE, Gavras H, Ravid K (2000) A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice. Biochim Biophys Acta 1500: 280-290.
59. Johnston-Cox HA, Ravid K (2011) Adenosine and blood platelets. Purinergic Signal 7: 357-365.
60. Lebon G, Warne T, Edwards PC, Bennett K, Langmead CJ, et al. (2011) Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474: 521-525.
61. Barrett NE, Holbrook L, Jones S, Kaiser WJ, Moraes LA, et al. (2008) Future innovations in anti-platelet therapies. Br J Pharmacol 154: 918-939.
62. Fukuoka T, Hattori K, Maruyama H, Hirayama M, Tanahashi N (2012) Laser-induced thrombus formation in mouse brain microvasculature: effect of clopidogrel. J Thromb Thrombolysis 34: 193-198.